Cabazitaxel
A semi-synthetic taxane and microtubule inhibitor for the treatment of hormone-refractory prostate cancer; possesses a favorable pharmacokinetic and safety profile, and a decreased propensity for P-glycoprotein (Pgp) -mediated drug resistance.Chemotherapeutic Agents Approved (In Vitro) :The cytotoxicity of cabazitaxel (100 μg/mL) on 4T1 cells without irradiation is 70.8%. Cabazitaxel (100 μg/mL) exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2%. (In Vivo) :Cabazitaxel (10 mg/kg, i.v.) has certain toxicity to liver and kidney but it can be avoided by integrated into Ans. The body weights of mice treated with AN-ICG-CBX and AN-CBX have a slightly decrease, while body weights of the free CBX group significantly decrease compared to the control group.
Product Specifications
CAS Number
183133-96-2
Product Name Alternative
XRP6258 | XRP 6258
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO: 93 mg/mL (111.3 mM) ; Ethanol: <1 mg/mL; Water: <1 mg/mL (< 1 mg/ml refers to the product slightly soluble or insoluble)
Smiles
Molecular Formula
C45H57NO14
Molecular Weight
835.932
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Enteroctopus dofleini Rhodopsin (RHO)
Recombinant Enteroctopus dofleini Rhodopsin (RHO)
